WuXi AppTec saw the highest growth of 1.99% in patent filings and 1.49% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.66% and grants by 0.66%. GlobalData’s DataBook provides a comprehensive analysis of WuXi AppTec‘s patent filings and grants. Buy the databook here.
WuXi AppTec has been focused on protecting inventions in United States(US) with 11 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 78% filings and 50% grants. The United States(US), China(CN), and European Patent Office(EPO) patent Office are among the top ten patent offices where WuXi AppTec is filings its patents. Among the top granted patent authorities, WuXi AppTec has 50% of its grants in United States(US), 38% in China(CN) and 12% in European Patent Office(EPO).
University of Pennsylvania and Johnson & Johnson could be the strongest competitors for WuXi AppTec
Patents related to rare diseases and healthtech lead WuXi AppTec's portfolio
WuXi AppTec has the highest number of patents in rare diseases followed by, healthtech and immuno-oncology. For rare diseases, nearly 67% of patents were filed and 33% of patents were granted in Q2 2024.
Parkinson's disease related patents lead WuXi AppTec portfolio followed by melanoma, and alzheimer's disease
WuXi AppTec has highest number of patents in parkinson's disease followed by melanoma, alzheimer's disease, dehydration, and psychiatric disorders. For parkinson's disease, nearly 2% of patents were filed and 5% of patents were granted in Q2 2024.
For comprehensive analysis of WuXi AppTec's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.